Retinal central vein occlusion
Also known as: Retinal, Retinae, Vein, Venous
Methodology & AI Transparency ⓘ
Retinal central vein occlusion Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Retinal central vein occlusion (also termed Retinal or Retinae)—coded clinically as H34.8192 across Eyes & Vision guidelines—combines AREDS2 macular nutrition [Retinal central vein occlusion H34.8192] with structured follow-up of Best-Corrected Visual Acuity in Retinal central vein occlusion (H34.8192: & OCT) (Intact retinal nerve fiber & macula (H34.8192)).
- 2 Real-world patient consensus: Diagnostic registry H34.8192: Retinal central vein occlusion is managed within Eyes & Vision (aka Retinal).
- 3 Typical cash cost range: Workup highlights for Retinal central vein occlusion (H34.8192): AREDS2 macular nutrition [Retinal central vein occlusion H34.8192].
- 4 Top reported side effects / signs: Follow-up benchmark in Retinal central vein occlusion: maintaining Intraocular Pressure (IOP) [Retinal central vein occlusion H34.8192] within 10 – 21 mmHg (individualized optic target) (H34.8192).
Ask our AI Specialists anything about Retinal central vein occlusion
What Is Retinal central vein occlusion?
Retinal central vein occlusion (also termed Retinal or Retinae)—coded clinically as H34.8192 across Eyes & Vision guidelines—combines AREDS2 macular nutrition [Retinal central vein occlusion H34.8192] with structured follow-up of Best-Corrected Visual Acuity in Retinal central vein occlusion (H34.8192: & OCT) (Intact retinal nerve fiber & macula (H34.8192)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Retinal central vein occlusion (code H34.8192) is microvascular diabetic/hypertensive retinopathy [Retinal central vein occlusion H34.8192], which Eye Health, Glaucoma & Vision Disorders clinicians address while surveilling Intraocular Pressure (IOP) [Retinal central vein occlusion H34.8192] (10 – 21 mmHg (individualized optic target) (H34.8192)).
Common Symptoms & Clinical Signs
- • Presentation of Retinal central vein occlusion (H34.8192): gritty burning, foreign-body in Retinal central vein occlusion (H34.8192: sensation, reflex tearing,)
- • Secondary Retinal central vein occlusion clinical sign: loss of peripheral in Retinal central vein occlusion (H34.8192: side vision)
- • Symptom flares in Retinal central vein occlusion correlating with Intraocular Pressure (IOP) [Retinal central vein occlusion H34.8192] deviation outside 10 – 21 mmHg (individualized optic target) (H34.8192)
- • Functional eyes & vision impact requiring AREDS2 macular nutrition [Retinal central vein occlusion H34.8192] evaluation (H34.8192)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Retinal central vein occlusion Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H34.8192 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Retinal central vein occlusion H34.8192] | 10 – 21 mmHg (individualized optic target) (H34.8192) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Retinal central vein occlusion (H34.8192: & OCT) | Intact retinal nerve fiber & macula (H34.8192) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Systemic in Retinal central vein occlusion (H34.8192: Blood Pressure) | Microvascular retinal protection (H34.8192) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Retinal central vein occlusion
Treatment selection for Retinal central vein occlusion depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Retinal central vein occlusion)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE: What a 1,752-Participant Study Found More stable CST was associated with better visual outcomes at the end of treatment suggesting that CST variability may provide a more reliable prognostic marker of visual outcomes than the presence of fluid alone, with the... Retina (Philadelphia, Pa.) • 2022-03-01 • Phase III Randomized Trial | N = 1,752 | 90/100 | PMID 34923515 ↗ |
| New Insights on Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular: What a 1,097-Participant Study Found A greater proportion of ranibizumab-treated eyes with nAMD gained/maintained visual acuity at SRF resolution. Ophthalmology. Retina • 2022-11-15 • Phase III Randomized Trial | N = 1,097 | 90/100 | PMID 35654363 ↗ |
| Can This Approach Help? Inside the Latest Research on Semaglutide, central retinal thickness and continuous glucose monitoring in Semaglutide treatment did not impact CRT beyond what could be explained by changes in glycaemia. Journal of diabetes and its complications • 2025-06-15 • Randomized Controlled Trial | N = 30 | 88/100 | PMID 40239470 ↗ |
| Can This Approach Help? Inside the Latest Research on Resolution of outer retinal abnormalities in eyes with vitreomacular traction ELM disruption, EZ disruption and/or SRF are present in a significant percentage of eyes with VMT without MH. The British journal of ophthalmology • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35288439 ↗ |
| Can This Approach Help? Inside the Latest Research on Retinal effects of 6 months of daily use of tadalafil or No abnormalities in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of tadalafil or sildenafil for 6 months. Archives of ophthalmology (Chicago, Ill. : 1960) • 2009-04-15 • Randomized Controlled Trial | N = 82 | 88/100 | PMID 19365010 ↗ |
Retinal central vein occlusion Patient Community & “People Like Me” Threads
Filter Retinal central vein occlusion community threads and patient logs by age, biological sex, dosage, and treatment duration.